🔎 Trials Near Me

Home › Kidney Failure › NCT05828823

Incremental Hemodialysis: The TwoPlus Trial

Recruiting

Comparative Effectiveness of an Individualized Model of Hemodialysis Versus Conventional Hemodialysis

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Patient eligibility Criteria:

Inclusion Criteria:

* Clinical Inclusion Criteria:
* Age ≥ 18 years
* Incident kidney dysfunction requiring dialysis (KDRD) started on maintenance, in-center hemodialysis (HD), or anticipated to be started on maintenance, in-center HD within the next 12 weeks
* Has received ≤36 sessions of intermittent HD (i.e., on HD for ≤12 weeks) at the time patient is approached for potential study participation

Residual Kidney Function Inclusion Criteria:

* Kidney urea clearance ≥ 2.0 mL/min
* Urine volume# of ≥500 mL/24 h

Exclusion Criteria:

* Pre-HD serum K ≥5.8 mEq/L, Na ≤125 mEq/L, or bicarbonate level ≤17 mEq/L
* Requirement or anticipated requirement of high-volume ultrafiltration
* Unable or unwilling to follow the study protocol for any reason
* Known pregnancy or planning to attempt to become pregnant or lactating women
* Estimated survival or dialysis modality change or center transfer \<6 months

Caregiver Eligibility Criteria:

* be at least 18 years old
* be the main caregiver (at patient's choice)
* be a close relative of the patient (spouse, child, sibling, parent, grandchild)
* have no known psychiatric and neurologic disorders (through direct inquiry from the person)
* not be a member of the medical or healthcare team
* not be the caregiver for another patient with chronic illness
* not have experienced severe life events within prior 3 months of enrollment (through direct inquiry from the person)

About the study

This study is to prospectively compare clinical effectiveness between clinically- matched incremental hemodialysis and conventional hemodialysis in patients with incident kidney dysfunction requiring dialysis and residual kidney function.

The study will enroll 350 patients on chronic hemodialysis and 140 caregivers of enrolled patients. Patients will be randomized in 1:1 ratio to either incremental start hemodialysis or conventional hemodialysis. Caregivers will be followed along with patients for an average period of 2 years post randomization.

What is being tested

Sponsor: Wake Forest University Health Sciences · Participants: 350 · Started: Feb 26, 2024

Contact the study team

Official record on ClinicalTrials.gov — NCT05828823

Locations in the U.S.

FloridaUniversity of Florida, Jacksonville
GeorgiaEmory University, Atlanta
MarylandJohns Hopkins University School of Medicine (JHUSM), Baltimore
MassachusettsMassachusetts General Hospital, Boston
MississippiUniversity of Mississippi Medical Center, Jackson
New YorkRenal Research Institute (RRI), New York
Northwell Health, Queens
North CarolinaUniversity of North Carolina Chapel Hill, Chapel Hill
Atrium Health Wake Forest Baptist, Winston-Salem
VirginiaUniversity of Virginia (UVA), Charlottesville

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.